Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.
Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J, Hoey T. Gurney A, et al. Among authors: axelrod f. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22. doi: 10.1073/pnas.1120068109. Epub 2012 Jul 2. Proc Natl Acad Sci U S A. 2012. PMID: 22753465 Free PMC article.
Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, Tang T, Wallace B, Wang M, Zhang C, Kapoun AM, Lewicki J, Gurney A, Hoey T. Yen WC, et al. Among authors: axelrod f. Clin Cancer Res. 2015 May 1;21(9):2084-95. doi: 10.1158/1078-0432.CCR-14-2808. Clin Cancer Res. 2015. PMID: 25934888
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J, Gurney A. Hoey T, et al. Among authors: axelrod f. Cell Stem Cell. 2009 Aug 7;5(2):168-77. doi: 10.1016/j.stem.2009.05.019. Cell Stem Cell. 2009. PMID: 19664991 Free article.
Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.
Chartier C, Raval J, Axelrod F, Bond C, Cain J, Dee-Hoskins C, Ma S, Fischer MM, Shah J, Wei J, Ji M, Lam A, Stroud M, Yen WC, Yeung P, Cancilla B, O'Young G, Wang M, Kapoun AM, Lewicki J, Hoey T, Gurney A. Chartier C, et al. Among authors: axelrod f. Cancer Res. 2016 Feb 1;76(3):713-23. doi: 10.1158/0008-5472.CAN-15-0561. Epub 2015 Dec 30. Cancer Res. 2016. PMID: 26719531
Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
Agnusdei V, Minuzzo S, Frasson C, Grassi A, Axelrod F, Satyal S, Gurney A, Hoey T, Seganfreddo E, Basso G, Valtorta S, Moresco RM, Amadori A, Indraccolo S. Agnusdei V, et al. Among authors: axelrod f. Leukemia. 2014 Feb;28(2):278-88. doi: 10.1038/leu.2013.183. Epub 2013 Jun 18. Leukemia. 2014. PMID: 23774673
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
Yuan TZ, Garg P, Wang L, Willis JR, Kwan E, Hernandez AGL, Tuscano E, Sever EN, Keane E, Soto C, Mucker EM, Fouch ME, Davidson E, Doranz BJ, Kailasan S, Aman MJ, Li H, Hooper JW, Saphire EO, Crowe JE, Liu Q, Axelrod F, Sato AK. Yuan TZ, et al. Among authors: axelrod f. MAbs. 2022 Jan-Dec;14(1):2002236. doi: 10.1080/19420862.2021.2002236. MAbs. 2022. PMID: 34967699 Free PMC article.
177 results